PDF(Pubmed)
Abstract：
UNASSIGNED: virological non-suppression is not only associated with increased risk of transmission of the Human Immunodeficiency virus (HIV) to others; perinatally and sexually, but it also decreases the life expectancy among the individuals who are on antiretroviral therapy (ART). This study sought to determine the level of virological non-suppression among ART patients from selected health facilities of a sub-district in uMgungundlovu district. This sub-district has high HIV transmission rates in KwaZulu Natal (KZN) and had one of the highest HIV prevalence in the district in 2018; population weighted HIV prevalence of 36.3% among men and women aged 15-49 years old, which was twice the average national prevalence of 18.8%.
UNASSIGNED: this descriptive, cross-sectional, and quantitative study was conducted among participants who were HIV-positive, 18 years old and above, and initiated on ART between January 2017 and January 2019 at selected PHC facilities of Vulindlela sub district. Health facility treatment registers, patient medical files and face-to-face interviews were used to collect the data and these were captured onto an Excel spreadsheet, cleaned, coded before importation into Epiinfo 17 for statistical analyses. Logistic regression analyses were conducted to investigate the factors associated with virological non-suppression.
UNASSIGNED: the study found a majority of participants were females (240/401 (60%)). The mean age of the participants was 38.1 (SD=11.2), with most participants who were between the ages of 29 and 39 years old (167 (41.7%)). Virological non-suppression was observed among 10% (40/401) of participants. The odds of virological non-suppression were higher among participants who were married (aOR 4.76, 95% CI 1.49-15.19; p=0.008).
UNASSIGNED: a virological non-suppression of 10% translates to viral suppression of 90%, which is below the target of UNAIDS 95-95-95 strategy. Hiding and skipping medication indicate how non-disclosure continues to hinder HIV treatment adherence. High odds of virological non-suppression among married participants indicate non-disclosure of the positive HIV status, or lack in spousal support.
UNASSIGNED: this descriptive, cross-sectional, and quantitative study was conducted among participants who were HIV-positive, 18 years old and above, and initiated on ART between January 2017 and January 2019 at selected PHC facilities of Vulindlela sub district. Health facility treatment registers, patient medical files and face-to-face interviews were used to collect the data and these were captured onto an Excel spreadsheet, cleaned, coded before importation into Epiinfo 17 for statistical analyses. Logistic regression analyses were conducted to investigate the factors associated with virological non-suppression.
UNASSIGNED: the study found a majority of participants were females (240/401 (60%)). The mean age of the participants was 38.1 (SD=11.2), with most participants who were between the ages of 29 and 39 years old (167 (41.7%)). Virological non-suppression was observed among 10% (40/401) of participants. The odds of virological non-suppression were higher among participants who were married (aOR 4.76, 95% CI 1.49-15.19; p=0.008).
UNASSIGNED: a virological non-suppression of 10% translates to viral suppression of 90%, which is below the target of UNAIDS 95-95-95 strategy. Hiding and skipping medication indicate how non-disclosure continues to hinder HIV treatment adherence. High odds of virological non-suppression among married participants indicate non-disclosure of the positive HIV status, or lack in spousal support.
摘要：
■病毒学非抑制不仅与人类免疫缺陷病毒（HIV）传播给他人的风险增加有关；围产期和性传播，但它也降低了接受抗逆转录病毒治疗(ART)的个体的预期寿命.这项研究旨在确定uMgungundlovu地区特定医疗机构中ART患者的病毒学非抑制水平。该分区在夸祖鲁纳塔尔省（KZN）的艾滋病毒传播率高，是2018年该地区艾滋病毒感染率最高的地区之一;15-49岁男女的人口加权艾滋病毒感染率为36.3％，是全国平均患病率18.8%的两倍。
■这个描述性的，横截面,在HIV阳性的参与者中进行了定量研究，18岁及以上,并于2017年1月至2019年1月在Vulindlela分区的选定PHC设施中启动ART。医疗机构治疗登记册，使用患者医疗档案和面对面访谈来收集数据，并将这些数据捕获到Excel电子表格中，清洁,在输入Epiinfo17进行统计分析之前编码。进行Logistic回归分析以探讨与病毒学非抑制相关的因素。
■研究发现大多数参与者是女性（240/401（60％））。参与者的平均年龄为38.1（SD=11.2），大多数参与者年龄在29至39岁之间（167（41.7％））。在10％（40/401）的参与者中观察到病毒学无抑制。在已婚的参与者中，病毒学非抑制的几率更高（aOR4.76，95％CI1.49-15.19；p=0.008）。
■10%的病毒学非抑制转化为90%的病毒抑制，低于联合国艾滋病规划署95-95-95战略的目标。隐藏和跳过药物表明不披露如何继续阻碍艾滋病毒治疗的依从性。已婚参与者中病毒学不抑制的可能性很高，表明未披露HIV阳性状态，或缺乏配偶支持。
■这个描述性的，横截面,在HIV阳性的参与者中进行了定量研究，18岁及以上,并于2017年1月至2019年1月在Vulindlela分区的选定PHC设施中启动ART。医疗机构治疗登记册，使用患者医疗档案和面对面访谈来收集数据，并将这些数据捕获到Excel电子表格中，清洁,在输入Epiinfo17进行统计分析之前编码。进行Logistic回归分析以探讨与病毒学非抑制相关的因素。
■研究发现大多数参与者是女性（240/401（60％））。参与者的平均年龄为38.1（SD=11.2），大多数参与者年龄在29至39岁之间（167（41.7％））。在10％（40/401）的参与者中观察到病毒学无抑制。在已婚的参与者中，病毒学非抑制的几率更高（aOR4.76，95％CI1.49-15.19；p=0.008）。
■10%的病毒学非抑制转化为90%的病毒抑制，低于联合国艾滋病规划署95-95-95战略的目标。隐藏和跳过药物表明不披露如何继续阻碍艾滋病毒治疗的依从性。已婚参与者中病毒学不抑制的可能性很高，表明未披露HIV阳性状态，或缺乏配偶支持。
